1297 related articles for article (PubMed ID: 11270668)
1. Advanced glycation end-products: a review.
Singh R; Barden A; Mori T; Beilin L
Diabetologia; 2001 Feb; 44(2):129-46. PubMed ID: 11270668
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation end products and diabetic complications.
Stitt AW; Jenkins AJ; Cooper ME
Expert Opin Investig Drugs; 2002 Sep; 11(9):1205-23. PubMed ID: 12225243
[TBL] [Abstract][Full Text] [Related]
3. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T
Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075
[TBL] [Abstract][Full Text] [Related]
4. TAGE (toxic AGEs) theory in diabetic complications.
Sato T; Iwaki M; Shimogaito N; Wu X; Yamagishi S; Takeuchi M
Curr Mol Med; 2006 May; 6(3):351-8. PubMed ID: 16712480
[TBL] [Abstract][Full Text] [Related]
5. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T
Curr Drug Discov Technol; 2006 Mar; 3(1):83-8. PubMed ID: 16712466
[TBL] [Abstract][Full Text] [Related]
6. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes.
Genuth S; Sun W; Cleary P; Sell DR; Dahms W; Malone J; Sivitz W; Monnier VM;
Diabetes; 2005 Nov; 54(11):3103-11. PubMed ID: 16249432
[TBL] [Abstract][Full Text] [Related]
7. Clinical review: The role of advanced glycation end products in progression and complications of diabetes.
Goh SY; Cooper ME
J Clin Endocrinol Metab; 2008 Apr; 93(4):1143-52. PubMed ID: 18182449
[TBL] [Abstract][Full Text] [Related]
8. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
Yamagishi S; Ueda S; Matsui T; Nakamura K; Okuda S
Curr Pharm Des; 2008; 14(10):962-8. PubMed ID: 18473846
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of diabetic nephropathy: a radical approach.
Salahudeen AK; Kanji V; Reckelhoff JF; Schmidt AM
Nephrol Dial Transplant; 1997 Apr; 12(4):664-8. PubMed ID: 9140991
[No Abstract] [Full Text] [Related]
10. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
11. Advanced Glycation End-Products and Diabetic Neuropathy of the Retina.
Oshitari T
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769249
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation end products, oxidative stress and diabetic nephropathy.
Yamagishi S; Matsui T
Oxid Med Cell Longev; 2010; 3(2):101-8. PubMed ID: 20716934
[TBL] [Abstract][Full Text] [Related]
13. Advanced glycation end products, their receptors and diabetic angiopathy.
Wautier JL; Guillausseau PJ
Diabetes Metab; 2001 Nov; 27(5 Pt 1):535-42. PubMed ID: 11694852
[TBL] [Abstract][Full Text] [Related]
14. Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?
Zhuang A; Forbes JM
Glycoconj J; 2016 Aug; 33(4):645-52. PubMed ID: 27270766
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation endproducts in diabetes and diabetic complications.
Vlassara H; Striker GE
Endocrinol Metab Clin North Am; 2013 Dec; 42(4):697-719. PubMed ID: 24286947
[TBL] [Abstract][Full Text] [Related]
16. Dietary advanced glycated end-products and medicines influence the expression of SIRT1 and DDOST in peripheral mononuclear cells from long-term type 1 diabetes patients.
Santos-Bezerra DP; Machado-Lima A; Monteiro MB; Admoni SN; Perez RV; Machado CG; Shimizu MH; Cavaleiro AM; Thieme K; Queiroz MS; Machado UF; Giannella-Neto D; Passarelli M; Corrêa-Giannella ML
Diab Vasc Dis Res; 2018 Jan; 15(1):81-89. PubMed ID: 29027826
[TBL] [Abstract][Full Text] [Related]
17. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a "glycoxidation-centric" point of view.
Chilelli NC; Burlina S; Lapolla A
Nutr Metab Cardiovasc Dis; 2013 Oct; 23(10):913-9. PubMed ID: 23786818
[TBL] [Abstract][Full Text] [Related]
18. [The role of advanced glycation end-products (AGEs) in the development of vascular diabetic complications].
Barbosa JH; Oliveira SL; Seara LT
Arq Bras Endocrinol Metabol; 2008 Aug; 52(6):940-50. PubMed ID: 18820805
[TBL] [Abstract][Full Text] [Related]
19. Dicarbonyls Generation, Toxicities, Detoxifications and Potential Roles in Diabetes Complications.
Alouffi S; Khan MWA
Curr Protein Pept Sci; 2020; 21(9):890-898. PubMed ID: 31660813
[TBL] [Abstract][Full Text] [Related]
20. [Antioxidant and anti-AGE therapeutics: evaluation and perspectives].
Bonnefont-Rousselot D
J Soc Biol; 2001; 195(4):391-8. PubMed ID: 11938556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
